secwatch.observer — SEC 8-K summary
======================================

Issuer:     Notable Labs, Ltd. (—)
CIK:        0001603207
Form:       8-K
Filed at:   2024-04-12T23:59:59+00:00
Accession:  0001493152-24-014394
Event type: earnings
Sentiment:  negative
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Notable Labs reports FY2023 net loss of $11.3M; cash of $8.2M as of Apr 1, 2024
-------------------------------------------------------------------------------

- Net loss $11.3M ($3.41 per share) vs $14.4M in 2022; revenue $0.3M from diagnostic services.
- Cash and equivalents $11.8M at Dec 31, 2023; $8.2M as of Apr 1, 2024; runway into Q4 2024.
- R&D expenses fell to $4.7M from $7.8M; G&A rose to $10.1M from $5.2M due to merger costs.
- Phase 2 volasertib/PPMP trial for r/r AML to start in coming months with dose-optimization lead-in.
- Company became public via reverse merger in October 2023; shares outstanding ~9.0M as of Apr 1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1603207/000149315224014394/0001493152-24-014394-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1603207/000149315224014394/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-014394

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer